For the medical treatment of PAH, three routes that target pulmonary vasodilators are used, namely the endothelin pathway, the prostacyclin receptor effects on receptors, and the nitric oxide-cyclic guanosine monophosphate biological pathway. This evidence concerns the gene PTGIR and pulmonary arterial hypertension.